Effect of Sinovac on Survival in Intensive Care Unit

Effect of Inactivated COVID-19 Vaccine, Sinovac on Survival in Intensive Care Unit

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04956562

Enrollment

Registered

2021-07-09

Start date

2021-04-01

Completion date

2021-05-15

Last updated

2021-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intensive Care Unit, Survival

Keywords

covid-19 vaccine, sinovac

Brief summary

Effect of Inactivated COVID-19 Vaccine (Sinovac) on survival in intensive care unit, Single Center Experience

Detailed description

Turkey has started vaccinate healthcare professionals at 13 January 2021 by Sinovac vaccine and declared a step by step inclusion schedule The primary aim of the study is to compare clinical, laboratory and survival data of COVID-19 patients who were vaccinated at least 14 days before enrollment to the study with COVID-19 patients not vaccinated although they would have. The secondary aim is to compare age of enrolled patients to ICU due to SARS-CoV-2 infection with patients admitted to ICU before start of vaccination program.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Inclusion criteria

* Patients with covid 19 over the age of 65 who were admitted to the intensive care unit between 1 April 2021 and 15 May 2021

Exclusion criteria

* admissions to ICU due to reasons other than COVID-19, age younger than 65, continued admission at the end of enrolment date,

Design outcomes

Primary

Measure	Time frame	Description
survival data	30 days	If the patient dies, we have reached an outcome

Countries

Turkey (Türkiye)

Outcome results